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Introduction. To evaluate clinical feasibility and reproducibility of cytometric bead assay (CBA) in nondiluted vitreous samples
of patients with age-related macular degeneration (ARMD), diabetic macular edema (DME), and central retinal vein occlusion
(CRVO). Methods. Twelve patients from a single clinics day qualiﬁed for intravitreal injections (ARMD n = 6, DME n = 3,
CRVO n = 3) and underwent a combination treatment including a single-site 23 gauge core vitrectomy which yielded a volume
of 0.6mL undiluted vitreous per patient. Interleukin-6 (IL-6), vascular endothelial growth factor isoform A (VEGF-A), and
monocyte chemo-attractant protein-1 (MCP-1) were assessed directly from 0.3mL at the same day (fresh samples). To assess the
reproducibility 0.3ml were frozen for 60 days at −80◦, on which the CBA was repeated (frozen samples). Results. In the fresh sam-
ples IL-6 was highest in CRVO (median IL-6 55.8pg/mL) > DME (50.6) > ARMD (3.1). Highest VEGF was measured in CRVO
(447.4) > DME (3.9) > ARMD (2.0). MCP-1 was highest in CRVO (595.7) > AMD (530.8) > DME (178). The CBA reproducibility
after frozen storage was examined to be most accurate for MCP1 (P = 0.91) > VEGF (P = 0.68) > IL-6 (P = 0.49). Conclusions.
CBA is an innovative, fast determining, and reliable technology to analyze proteins in ﬂuids, like the undiluted vitreous, which is
important to better understand ocular pathophysiology and pharmacology. There is no inﬂuence of intermittent storage at −80◦
for the reproducibility of the CBA.
1.Introduction
The measurement of ocular inﬂammatory and angiogenic
cytokines has become increasingly important in the era of
intravitreal drug therapy in many retinal diseases, primarily
age-relatedmaculardegeneration(ARMD),diabeticmacular
edema (DME), and retinal vein occlusion (RVO) [1–3]. In
the ﬁeld of ophthalmology, clinical and preclinical studies
are up to date based primarily on ELISA (enzyme-linked im-
munosorbent assay) results, which have been utilized exten-
sively to understand the expression of cytokines from the
ocular tissues (choroid, retinal pigment epithelium, retina).
The quantitative analysis of a single factor analysis, however,
requires for each measurement about 0.4 cc of ﬂuid and 360
minutes of laboratory time. A new, innovative technique, the
cytometric bead array (CBA) technology, provides in con-
trast a quantitative analysis of multiple markers in various
specimen,requiresasmallersamplevolume,andistime-and
cost-eﬀective [4]. It is based on the ﬂow cytometry, which
is an analytical tool that allows a discrimination of diﬀerent
particles on the basis of size and/or color.
It has been shown earlier, using serum or blood samples,
that CBA and ELISA results correlated well [5]. It is matter of
debate, however, if CBA and ELISA values of undiluted vit-
reous are comparable under various clinical and laboratory
conditions in ophthalmology. Until today, Maier et al. were
the only ones to demonstrate that vitreous and serum
concentrations of cytokines, including vascular endothelial
growth factor (VEGF), determined by CBA showed a strong
correlation with those measured by ELISA in patients with
advanced diabetic retinopathy that had to undergo three-
port vitrectomy [6]. Additionally it is not clear, from a labo-
ratory point of view, if the CBA results are reproducible after
intermittent storage at −80◦C, which often happens in the
clinical and laboratory routine. Furthermore it is interesting
to assess the CBA technique for the detection of inﬂamma-
tory and proangiogenic cytokines in patients that would2 Journal of Ophthalmology
qualify for an intravitreal injection with anti-VEGF, steroids,
oracombinationtherapyofbothagentsduetoavisioncom-
promisingmacularedema.Themajorityofdataderivesfrom
aqueous samples so far [7], which is important as aqueous
samples should correlate well with the vitreous samples, but
theabsoluteconcentrationsofcytokinesinthetwoﬂuidsdif-
fer signiﬁcantly [8]. Before establishing a new method like
the CBA in ophthalmology, it is important to evaluate the
clinical feasibility and reproducibility with vitreous ﬂuid.
In this study concentrations of interleukin-6 (IL-6), vas-
cular endothelial growth factor (VEGF), and monocyte che-
moattractant protein-1 (MCP-1) were analyzed from undi-
luted, cut vitreous samples from patients with age related
macular degeneration (ARMD), diabetic macular edema
(DME), and central retinal vein occlusion (CRVO), which
qualiﬁed for intravitreal injections on one clinical day.
2. Methods
2.1. Study Population. Twelve patients were included in the
presentstudy:sixage-relatedmaculardegeneration(ARMD)
patients (age 77.9±6.9 years) with an active occult choroidal
neovascularization and an average central macular thickness
of 368 ± 45μm measured by spectral optical coherence
tomography (OCT; 3D OCT-2000; Topcon Deutschland,
Willich, Germany), three patients with diabetic macular
edema(DME;age66.8±10.5years)andameancentralmac-
ular thickness of 508 ± 108μm, and three patients (69.5 ±
14.2) with central retinal vein occlusion (CRVO) with a
historyof11weeks ±3weeksofCRVOandacentralmacular
thickness of 557 ± 125μm. The indications for the treatment
werevisualacuity decreasing macularedema adhering to our
concept of combined therapy [9, 10].
Exclusion criteria for this series of patients were previous
intraocular surgery, acute ocular infection, uveitis, trauma,
vitreous hemorrhage, and retinal detachment.
Collection of samples was performed after local full
ethics committee approval (57/08) in accordance with the
EuropeanGuidelinesforGoodClinicalPracticeandtheDec-
laration of Helsinki. Informed consent was obtained from
each patient before the start of therapy.
2.2. Statistical Analysis. Data were analyzed using Bias soft-
ware (Version 8.3.8, Epsilon, Darmstadt, Germany) for Win-
dows. All tests were performed at an error level of 5%.
David’s test was used to check for distribution of data. To
determine the inﬂuence of intermittent storage the nonpara-
metric Wilcoxon-matched pair-test was used including the
Hodge-Lehmann indicator, which compares the variance of
the results tested with the 95% conﬁdence interval.
2.3. Sample Collection and Preparation. A limited core pars
plana vitrectomy was performed using a single-site 23 gauge
vitrector (Intrector, Insight Instruments, Stuart, FL, USA),
which has two separate channels for aspiration and infusion.
After conjunctival displacement an oblique sclerotomy was
performed to illuminate the tip of the vitrector with a head-
set and a magnifying 28 diopters lens in the mid-vitreous
cavity. An assistant then aspirated a total of 0.6mL undiluted
andcutmidandposteriorvitreousinstructedbythesurgeon,
who controlled clinical relevant perioperative hypotonia.
Thus a minimum sample volume of 0.3mL vitreous was
available for “fresh” direct CBA analysis on the same day and
0.3mL “frozen” samples were available for storage at −80◦C
to test the CBA reproducibility. At the end of the limited pos-
terior core vitrectomy a subsequent isovolumic substitution
of balanced salt solution (BSS, ALCON, Freiburg, Germany,
0.3mL), 1.25mg (0.1mL) bevacizumab (Avastin, Genen-
tech, San Fransisco, CA, USA), and 0.8mg (0.2mL) dex-
amethasone(Dexa-ratiopharm,Ulm,Germany)wasinjected
adhering to the concept of combination treatment in these
retinal diseases [9, 10].
2.4. Cytokines
2.4.1. IL-6. Interleukin-6 (IL-6) is a mediating protein dur-
ing inﬂammation processes and the maturation of B cells.
The protein is primarily produced at sites of acute and chro-
nic inﬂammation, where it is secreted into the serum and
induces a transcriptional inﬂammatory response through
IL-6 receptor-alpha, which is associated with VEGF expres-
sion [11]. In ophthalmology it is described in a wide variety
of inﬂammation-associated disease states what clinically can
b es e e na sam a c u l a re d e m ad u r i n gD M Ea n dR V O[ 1, 3, 12].
2.4.2. VEGF. Vascular endothelial growth factor (VEGF)
under physiologic normal conditions is expressed in the RPE
for the retinal metabolism and balances the fenestration and
the nutrition of the choriocapillaris [13]. Overexpression of
VEGF, however, is induced in retinal cells mainly by hypoxia
and IL-6 and leads to increased vascular permeability [11],
like in a choroidal neovascularization, diabetic retinopathy,
a n df u r t h e r m o s ti nr e t i n a lv e i no c c l u s i o n[ 14]. It may seem
that the expression of VEGF is associated with the total area
of ischemic retina [15].
2.4.3. MCP-1. Monocytic chemotactic protein-1 (MCP-1) is
a member of the CC chemokines (Cystein-cystein chemoki-
nes). Immune cells, such as monocytes, are recruited by the
expression of MCP-1. It is produced by retinal endothelial
cells and has been implicated in leukostasis in the hypoxic
retina and can thus be induced by VEGF [16, 17]. Previous
data presumed MCP-1 as a potential factor in the prolifera-
t i v ep h a s eo fD R[ 18].
2.5. Cytometric BEAD Assay (CBA). Amounts of VEGF-A,
IL-6, and MCP-1 were determined using the cytometric bead
array system (BD, Heidelberg, Germany). Experiments were
carried out following the manufacture’s instruction manual.
In brief, 50μL of each vitreous body sample was incubated
for 1h with appropriate amounts of detection beads, which
werespeciﬁcforeachinvestigatedfactor.Afterwards,samples
were incubated for 2h with detection reagent, which again
was speciﬁc for each used detection bead. Samples were
measured on a FACS Canto II (BD, Heidelberg, Germany)
and analysed by FCAP array software (BD, Heidelberg, Ger-
many). The amount of VEGF, IL-6, and MCP-1 was calcu-
lated using a speciﬁc standard curve (in pg/mL). The CBAJournal of Ophthalmology 3
Table 1 :P r o t e i nv a l u e si np g / m Lo fA M D( n = 6), DME (n = 3),
and CRVO (n = 3) patients.
N = 12 Fresh samples Frozen samples
Median
1.Quartile/3.Quartile
Median
1.Quartile/3.Quartile
IL-6 10.8 10.4
2.5/249.1 3.2/237.7
ARMD (n = 6) 3.1 4.8
2.4/60.2 3.2/114.3
DME (n = 3) 50.6 55.7
3.5/89.0 4.4/99.1
CRVO (n = 3) 55.8 51.7
12.2/149.1 9.9/237.7
VEGF 4.0 4.1
1.5/454.0 1.3/421.1
ARMD (n = 6) 2.0 2.2
1.5/4.1 1.3/3.9
DME (n = 3) 3.9 4.6
3.6/46.5 4.4/54.5
CRVO (n = 3) 447.4 414.7
51.8/454.0 38.6/421.1
MCP-1 435 395.9
42.9/2397.8 42.1/2055.5
ARMD (n = 6) 530.8 306.7
38.3/768.3 42.1/1115.3
DME (n = 3) 178.0 164.4
147.5/339.8 164.4/363.7
CRVO (n = 3) 595.7 601.2
463.1/2397.8 482.0/2055.5
was repeated in theses samples, that were acquired during
surgery and stored at −80◦Cf o r6 0d a y s .
3. Results
3.1. CBA. In the fresh samples IL-6 was highest in CRVO
(median IL-6 55.8pg/mL; 95% conﬁdence interval 12.2–
149.1) > DME (50.6; 3.5–89) > ARMD (3.1; 2.4–60.2). High-
est VEGF was measured in CRVO (447.4; 51.8–454) > DME
(3.9; 3.6–46.5) > AMD (2.0; 1.5–4.1). MCP-1 was higher in
CRVO (595.7; 463.1–2397.8) > AMD (530.8; 38.3–768.3) >
DME (178; 147.5–339.8; Table 1).
In the frozen samples IL-6 was highest in DME (55.7;
4.4–99.1) > CRVO (51.7; 9.9–237.7) > ARMD (4.8; 3.2–
114.3). VEGF was highest in the CRVO group (414.7;
38.6–421.1) > DME (4.6; 4.4–54.5) > ARMD (2.2; 1.3–3.9).
MCP-1 was highest in CRVO (601.2; 482–2055) > ARMD
(306.7; 42.1–1115.3) > DME (164.4; 164.4–363.7).
None of the data were parametrically distributed (P =
0.67 David’s test).
3.2. CBA Reproducibility. The values of the fresh versus
frozen values were not statistically signiﬁcant and thus com-
parable for all three proteins tested and most accurate for
Table 2: Comparison of fresh samples and frozen stored samples
using the Wilcoxon-matched pair-test including the Hodges-Lehm-
ann indicator.
IL-6 fresh
versus frozen
VEGF fresh
versus frozen
MCP-1 fresh
versus frozen
P = 0.49 P = 0.68 P = 0.91
Diﬀerence of
Hodges-
Lehmann
−0.85 −1.9 2.5
MCP1 (P = 0.91) > VEGF (P = 0.68) > IL-6 (P = 0.49).
Additionally, the diﬀerence of Hodge-Lehmann, which indi-
cates the overall median deviation of the speciﬁc protein
levels, proves that there is no signiﬁcant diﬀerence in factor
levels after storage (Table 2). In general, there is no degener-
ation of vitreous IL-6, MCP-1, and VEGF caused by storage
at −80◦Cf o r6 0d a y s .
4. Discussion
This study was intended to evaluate the feasibility and repro-
ducibility of cytometric bead assay (CBA) in a routine clinics
and laboratory day setting. It was not intended to measure
cytokine levels per disease, as the major limitation of this
study is the small sample size. We demonstrated feasibility
to assess the undiluted vitreous samples of 12 patients by
performing surgery in the morning, aspirate 0.6mL per
patient, and analyze 0.3mL of the probes directly on the
same day three hours later. We observed cytokine levels for
RVO and DME that were in accordance with the literature.
There is to the best of our knowledge so far no evidence
on the levels of intraocular cytokines of undiluted vitreous
samples in AMD. In theory a greater number of fresh AMD
samples could easily be gained on the basis of our protocol
from a day’s surgical program. In a clinical routine, however,
it is questionable if enough fresh samples can be acquired
and therefore intermittent storage needs to be evaluated.
The other 0.3mL of the probes were therefore frozen at
−80 intermittent storage to later test if the results are repro-
ducible. We could not detect any statistical signiﬁcant dege-
nerationofcytokines(IL-6P = 0.49;VEGFP = 0.68;MCP-1
P = 0.91) and conclude that storage of vitreous samples does
not alter the cytokine levels and that results of previously
stored and immediately analyzed samples are comparable.
Thereisalargebodyofevidenceindicatingthatcytokines
mediating angiogenic and inﬂammatory processes in the
choroid, the RPE, and the retina, like IL-6, VEGF, and MCP-
1, contribute to the pathogenesis of ARMD, RVO, and DME
[7, 19, 20]. Additionally it could be demonstrated that, in
vitreous samples of patients that qualiﬁed for three-port pars
plana vitrectomy, due to proliferative disease conversion,
the concentration of these angiogenic factors is increased,
which was demonstrated by the majority of cases with ELISA
[1, 3]. We are aware, however, that this small series of patient
samples without a control group and that it is not able
draw conclusions about cytokines in these diseases. Instead
we could demonstrate that cytometric Bead Assay (CBA)
is a time- and cost-eﬀective tool and—in comparison to4 Journal of Ophthalmology
ELISA—a powerful technique to analyze a larger number of
samples in various retinal diseases. In comparison to ELISA
only one cytokine could have been analyzed from the sample
size in our study, would have generated more time, and
w o u l dt h u sh a v eb e e nm o r ee x p e n s i v e .
5. Conclusion
In AMD, DME, and RVO the clinical importance of frequent
intravitreal anti-VEGF or steroid therapy, which is drawn
upon clinical observation with OCT or ﬂuorescein angiogra-
phy and not upon a direct biological feedback mechanism,
warrants the evaluation of new analytical techniques like
CBA.
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